AAPS PharmSci 360

AI and computational psychiatry: Finding ‘hidden cues’

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: Artificial intelligence, psychiatrics, psychiatry, preclinical, Clinical research, Drug discovery, Patient centricity, Patient, schizophrenia, mental illness

The pharmaceutical industry has increasingly been adopting artificial intelligence – which has demonstrated the ability to predict instances of schizophrenia with 74% accuracy.

There are many ways in which researchers are using artificial intelligence (AI), said Guillermo Cecchi, principal research staff member, manager of computational psychiatry at IBM, who spoke at AAPS PharmSci 360.

“We are using AI also to find hidden cues that may escape clinicians due to various factors, including their complexity (e.g. a combination of several disparate features) or the impossibility to even detect them (e.g. high frequency features of the voice),”​ Cecchi told us.

Cecchi’s research in computational psychiatry – defined by the National Institute of Mental Health as way to identify and validate biomarkers and treatment targets related to psychiatric disorders – has demonstrated AI’s ability to predict the likelihood of a previously-unseen patient​ having schizophrenia.

According to a study conducted in collaboration by IBM and researchers at the University of Alberta, AI and machine learning algorithms can predict instances of schizophrenia with 74% accuracy​.

Schizophrenia is an area in which machine-based research has proved to be useful, as the condition leaves a strong trace in language​.

“The value of using AI for language is that we can 'standardize' the diagnosis of different mental health conditions, as we can precise the features that define them – as far as they are reflected in language,” ​explained Cecchi.

However, schizophrenia​ is not the only mental illness​ in which AI and machine learning can be applied. Cecchi told us that other psychiatric conditions, such as bipolar disorder, borderline personality disorder, depression, addiction, anxiety disorders, as well as neurologic conditions like Parkinson’s and Alzheimer’s can use AI to make further assessments.

Cecchi said, “I think that the most significant insight we have gained is that it is possible to predict with high accuracy the onset of psychosis in an at-risk population. While we still need to conduct further and more extensive validation studies, the initial studies make us believe we have found a real and robust signal.”

“This has many implications for early intervention and for monitoring of treatment outcomes, including clinical trials,”​ he added.

Information technology and is also making it possible to complete remote-monitoring​ of patients at high frequency, explained Cecchi. 

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars